ArticleJournal of cancer research and clinical oncology2026
High serum ferritin is associated with genetic instability in myelodysplastic neoplasms.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSerum ferritin is an independent prognostic marker in myelodysplastic neoplasms (MDS) and serves as a surrogate parameter for iron overload. Oxidative stress derived from iron overload may induce genomic damage, thereby promoting genetic instability and disease progression in MDS. We aimed to evaluate a possible association between iron overload via serum ferritin and various parameters for genetic instability in MDS.
methodsFifty-one patients with confirmed MDS were analyzed and divided into three groups based on ferritin levels: non-elevated (≤ 275 µg/L), moderately elevated (> 275 and < 1000 µg/L), and highly elevated (≥ 1000 µg/L). Genetic instability was assessed by cytogenetic analysis and somatic mutation profiling. DNA double-strand breaks were quantified by γH2AX-foci in CD34+ peripheral blood cells, and telomere length was measured by flow-FISH.
resultsElevated serum ferritin was associated with increased cytogenetic abnormalities and somatic mutations at genomic regions commonly involved in MDS, higher levels of double-strand breaks, and shortened telomeres in granulocytes but not in lymphocytes. Markers of early-stage genetic instability, such as double-strand breaks and telomere shortening in granulocytes, were detectable at moderately elevated ferritin > 275 µg/L, whereas markers for advanced-stage genetic aberrations, including somatic mutations and cytogenetic aberrations, were more prominent at ferritin levels ≥ 1000 µg/L.
conclusionThese findings support the hypothesis that iron overload, reflected by elevated ferritin as surrogate parameter, may contribute to and/or increase genetic instability in MDS patients with ineffective hematopoiesis. Notably, correlations were observed at ferritin levels below current thresholds for initiating iron chelation therapy, indicating clinical relevance early in the disease course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.